Open AccessAssessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Author(s) -
Michael F. Press,
José A. Seoane,
Christina Curtis,
Emmanuel Quinaux,
Roberta Guzman,
Guido Sauter,
W. Eiermann,
John R. Mackey,
Nicholas J. Robert,
Tadeusz Pieńkowski,
John Crown,
Miguel Martín,
Vicente Valero,
Valerie Bée,
Yanling Ma,
Ivonne Villalobos,
Dennis J. Slamon
Publication year - 2018
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2018.6012
Subject(s) - medicine , breast cancer , oncology , fluorescence in situ hybridization , clinical trial , cohort , clinical oncology , fish <actinopterygii> , cancer , chromosome , gene , biochemistry , chemistry , fishery , biology
The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an "equivocal" category (average HER2 copies per tumor cell ≥4-6 with HER2/CEP17 ratio <2.0) to be resolved as negative or positive by assessments with alternative control probes. Approximately 4% to 12% of all invasive breast cancers are characterized as HER2-equivocal based on FISH.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom